Abstract
Anti-inflammatory drugs consist of non-steroidal anti-inflammatory drugs (NSAIDs) including non-selective nsNSAIDs, aspirin, and cyclooxygenase-2 (COX-2)-selective inhibitors also referred to as coxibs, and glucocorticoids (GCs). They are worldwide prescribed drugs for many musculoskeletal conditions, such as osteoarthritis and inflammatory rheumatic diseases. Anti-inflammatory drugs can exert deleterious effects on the cardiovascular system, excluding aspirin. NSAIDs, especially coxibs, have been demonstrated to increase cardiovascular risk and have generated many concerns leading to the reassessment of their benefit/risk ratio. GCs may also induce cardiovascular events, but evidence seems to be less clear. Before prescribing these drugs, an assessment of cardiovascular risk may be judicious. In this review, anti-inflammatory drugs, coxibs, nsNSAIDs and GCs, and the risk of cardiovascular events will be discussed.
Keywords: Cardiovascular system, cardiovascular diseases, anti-inflammatory agents, NSAIDs, cyclooxygenase 2 inhibitors, glucocorticoids
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:Cardiovascular Adverse Effects of Anti-Inflammatory Drugs
Volume: 12 Issue: 1
Author(s): Camille Roubille, Johanne Martel-Pelletier, Jean-Marc Davy, Boulos Haraoui and Jean-Pierre Pelletier
Affiliation:
Keywords: Cardiovascular system, cardiovascular diseases, anti-inflammatory agents, NSAIDs, cyclooxygenase 2 inhibitors, glucocorticoids
Abstract: Anti-inflammatory drugs consist of non-steroidal anti-inflammatory drugs (NSAIDs) including non-selective nsNSAIDs, aspirin, and cyclooxygenase-2 (COX-2)-selective inhibitors also referred to as coxibs, and glucocorticoids (GCs). They are worldwide prescribed drugs for many musculoskeletal conditions, such as osteoarthritis and inflammatory rheumatic diseases. Anti-inflammatory drugs can exert deleterious effects on the cardiovascular system, excluding aspirin. NSAIDs, especially coxibs, have been demonstrated to increase cardiovascular risk and have generated many concerns leading to the reassessment of their benefit/risk ratio. GCs may also induce cardiovascular events, but evidence seems to be less clear. Before prescribing these drugs, an assessment of cardiovascular risk may be judicious. In this review, anti-inflammatory drugs, coxibs, nsNSAIDs and GCs, and the risk of cardiovascular events will be discussed.
Export Options
About this article
Cite this article as:
Roubille Camille, Martel-Pelletier Johanne, Davy Jean-Marc, Haraoui Boulos and Pelletier Jean-Pierre, Cardiovascular Adverse Effects of Anti-Inflammatory Drugs, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2013; 12 (1) . https://dx.doi.org/10.2174/1871523011312010008
DOI https://dx.doi.org/10.2174/1871523011312010008 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
What Changes we may Expect in 2010 Hypertension Diagnosis and Management: Insights from the European Update Document
Current Vascular Pharmacology Perinatal Management of Fetal Tumors
Current Pediatric Reviews Noscapine-loaded PLA Nanoparticles: Systematic Study of Effect of Formulation and Process Variables on Particle Size, Drug Loading and Entrapment Efficiency
Pharmaceutical Nanotechnology A Comprehensive Literature Review of COPD-Related Fatigue
Current Respiratory Medicine Reviews Editorial (Thematic Issue: Disease Control and Active and Healthy Ageing: New Paradigms of Therapeutic Strategy)
Current Pharmaceutical Design Psychological Treatments for Cognitive Dysfunction in Major Depressive Disorder: Current Evidence and Perspectives<sup>§</sup>
CNS & Neurological Disorders - Drug Targets Optimal Antibiotic Therapy in the Management of the Lung of the Critically Ill
Current Respiratory Medicine Reviews Endoplasmic Reticulum Stress and Atherosclerosis
Current Hypertension Reviews Targeting Toll-like Receptors in Autoimmunity
Current Drug Targets Disrupted White Matter Networks from Subjective Memory Impairment to Amnestic Mild Cognitive Impairment
Current Alzheimer Research Identification and Treatment of Patients with Homozygous Familial Hypercholesterolaemia: Information and Recommendations from a Middle East Advisory Panel
Current Vascular Pharmacology Withdrawal Notice: Design and Analysis of Optimization and Tuning in Data Warehouses Using Bitmap Indexes
Recent Advances in Computer Science and Communications Cholesteryl Ester Transfer Protein: Pharmacological Inhibition for the Modulation of Plasma Cholesterol Levels and Promising Target for the Prevention of Atherosclerosis.
Current Topics in Medicinal Chemistry Role of PPAR-γ Agonist Thiazolidinediones in Treatment of Pre-Diabetic and Diabetic Individuals: A Cardiovascular Perspective
Current Drug Targets - Cardiovascular & Hematological Disorders Cardiac Cell Therapy and Bypass Surgery
Current Pharmaceutical Design NAD in Skin: Therapeutic Approaches for Niacin
Current Pharmaceutical Design Opposing Gatekeepers of Apical Sterol Transport: Niemann-Pick C1-Like 1 (NPC1L1) and ATP-Binding Cassette Transporters G5 and G8 (ABCG5/ABCG8)
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Impact of Pre-Diabetes and Diabetes on Cardiovascular Outcomes
Current Vascular Pharmacology How Much Gets there and What Does it Do?: The Need for Better Pharmacokinetic and Pharmacodynamic Endpoints in Contemporary Drug Discovery and Development
Current Pharmaceutical Design Epidemiology of Ischemic Heart Disease and Diabetes in South Asia: An Overview of the Twin Epidemic
Current Diabetes Reviews